Compare ZLAB & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 9.3B |
| IPO Year | 2017 | 2016 |
| Metric | ZLAB | PTGX |
|---|---|---|
| Price | $25.92 | $139.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $49.60 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 760.5K | 562.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $460,156,000.00 | N/A |
| Revenue This Year | $9.75 | $874.25 |
| Revenue Next Year | $26.03 | N/A |
| P/E Ratio | ★ N/A | $60.61 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $62.24 |
| 52 Week High | $34.72 | $160.81 |
| Indicator | ZLAB | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 41.98 |
| Support Level | $24.81 | $130.63 |
| Resistance Level | $27.20 | $142.20 |
| Average True Range (ATR) | 0.82 | 4.88 |
| MACD | -0.11 | -0.71 |
| Stochastic Oscillator | 63.71 | 30.28 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.